As GzmB expression is promoted by the JAK/STAT signaling pathway (58) and reduced in mice treated with the JAK/STAT inhibitor tofacitinib (59), this may explain the discrepancies in GzmB levels measured in the SF of patients with IA (RA and non-RA). Here, SOAT1 is linked to rheumatoid arthritis.